Paper · 19252434
Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
Ruemmele P and 19 others. Am J Surg Pathol, 2009. Cited by 99 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Papers, record 19252434. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19252434
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions.
- PubMed
Topics38
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Adenoma | Major topic |
| Ampulla of Vater | Major topic |
| Carcinoma | Major topic |
| Common Bile Duct Neoplasms | Major topic |
| DNA Mismatch Repair | Major topic |
| Gene Expression Regulation, Neoplastic | Major topic |
| Microsatellite Instability | Major topic |
| Precancerous Conditions | Major topic |
| Adaptor Proteins, Signal Transducing | |
| Adenocarcinoma | |
| Adenocarcinoma, Mucinous | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Carcinoma, Papillary | |
| Cell Differentiation | |
| DNA Methylation | |
| DNA-Binding Proteins | |
| Europe | |
| Female | |
| Gene Deletion | |
| Genotype | |
| Humans | |
| Immunohistochemistry | |
| Kaplan-Meier Estimate | |
| Male | |
| Middle Aged | |
| MutL Protein Homolog 1 | |
| MutS Homolog 2 Protein | |
| Neoplasm Invasiveness | |
| Neoplasm Staging | |
| Nuclear Proteins | |
| Phenotype | |
| Polymerase Chain Reaction | |
| Promoter Regions, Genetic | |
| Proportional Hazards Models | |
| Risk Assessment | |
| Treatment Outcome |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References0
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
None in this release.
Cited by57
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 99 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,877,472 | Sporadic ampullary adenoma mimicking adenocarcinoma in the absence of genetic predisposition: a case report. | J Surg Case Rep | 2026 | https://conductscience.org/library/papers/42877472 | PubMed |
| 42,645,512 | Tumours of the duodenum and the ampulla of Vater: An overview of the key criteria for their classification, pathogenesis, and molecular assessment. | Virchows Arch | 2026 | https://conductscience.org/library/papers/42645512 | PubMed |
| 40,522,349 | Signet ring cell adenocarcinoma of the ampulla of Vater: does the presence of signet ring cells always suggest a poorer outcome? | Langenbecks Arch Surg | 2025 | https://conductscience.org/library/papers/40522349 | PubMed |
| 39,005,199 | Challenges and Advancements in Palliative Chemotherapy for Ampullary Adenocarcinoma. | Gut Liver | 2024 | https://conductscience.org/library/papers/39005199 | PubMed |
| 38,130,162 | Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study. | Gut Liver | 2024 | https://conductscience.org/library/papers/38130162 | PubMed |
| 38,015,261 | The timing of recurrence after endoscopic papillectomy. | Surg Endosc | 2024 | https://conductscience.org/library/papers/38015261 | PubMed |
| 37,876,255 | [Treatment of Ampullary Adenocarcinoma]. | Korean J Gastroenterol | 2023 | https://conductscience.org/library/papers/37876255 | PubMed |
| 37,504,367 | Ampullary Cancer: Histological Subtypes, Markers, and Clinical Behaviour-State of the Art and Perspectives. | Curr Oncol | 2023 | https://conductscience.org/library/papers/37504367 | PubMed |
| 37,046,631 | Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer: Adding New Flavors to the Pizza. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37046631 | PubMed |
| 36,902,170 | DNA Damage and Its Role in Cancer Therapeutics. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36902170 | PubMed |
1 to 10 of 57
See all 57 cited byGenes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MLH1 | 4,292 | PubTator's text mining | https://conductscience.org/library/genes/4292 | NCBI Gene |
| MSH2 | 4,436 | PubTator's text mining | https://conductscience.org/library/genes/4436 | NCBI Gene |
| MSH6 | 2,956 | PubTator's text mining | https://conductscience.org/library/genes/2956 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/19252434
GET https://conductscience.org/api/papers/v1/19252434/cited_by?page=2